Recruiting Geographic Atrophy Studies in Jacksonville
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cance...
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in ped...
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
The main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the doubl...
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module...
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction canc...
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and h...
About Geographic Atrophy Clinical Trials in Jacksonville
Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.
There are currently 7 geographic atrophy clinical trials recruiting participants in Jacksonville, FLORIDA. These studies are seeking a combined 1,561 participants. Research is being sponsored by AstraZeneca, SK Life Science, Inc., Hoffmann-La Roche and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Geographic Atrophy Clinical Trials in Jacksonville — FAQ
Are there geographic atrophy clinical trials in Jacksonville?
Yes, there are 7 geographic atrophy clinical trials currently recruiting in Jacksonville, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Jacksonville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Jacksonville research site will contact you about next steps.
Are clinical trials in Jacksonville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Jacksonville studies also compensate for your time and travel.
What geographic atrophy treatments are being tested?
The 7 active trials in Jacksonville are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov